Intellia Therapeutics, Inc. (NASDAQ:Northern) among the 11 best genomics stock to buy according to hedge funds. He subsequently presented three years' encouragement data from their Phase 1 trial of Lonvoguran Zicleran (Lonvo-Z) in patients with hereditary angioedema (HAE) at the EAACI 2025 Congress.
Laboratory scientist looking into a microscope focusing on gene editing technology.
All 10 patients were free from attacks and treatment for a median of 23 months after receiving a single dose of Lonvo-Z, which resulted in a 98% mean reduction in monthly HAE attacks. Positive security results took place across all treatment portions. The phase 3 current trial has a majority of US registration and has completed screening before schedule. Intellia Therapeutics, Inc. (NASDAQ: NTLA) plans to launch in 2027 after the introduction of a Bla in 2026.
Lonvo-Z (NTLA-2002) is a in Vivo Crispr experimental gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The FDA is designated as an orphan and RMAT, while the EMA is designated prime, among other regulatory classes.
Intravenously administered in doses ranging from 25 to 75 mg, the therapy showed a kallikrein protein reduction that is dependent on dose and long-term effectiveness, with no major side effects associated with recorded treatment.
While we recognize the potential of NTLA as an investment, we believe that some AI stocks offer more upside down potential and carry less of a disadvantage risk. If you are looking for a highly underestimated AI stock that also stands to benefit significant The best short -term stock.
Read Next: 10 high growth ev stock to invest in and 13 Best car stock to buy in 2025.
Disclosure. Nothing.